Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb, randomized, double-blind, placebo-controlled, parallel dosing group trial studying the efficacy and safety of high and low doses of pudafensine as well as placebo in patients suffering from severe to moderate erectile dysfunction (ED)

Next Previous
Search
Trial Profile

A phase IIb, randomized, double-blind, placebo-controlled, parallel dosing group trial studying the efficacy and safety of high and low doses of pudafensine as well as placebo in patients suffering from severe to moderate erectile dysfunction (ED)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pudafensine (Primary)
  • Indications Erectile dysfunction
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Jul 2023 New trial record
    • 29 Jun 2023 According to an Initiator Pharma media release, last patients are undergoing the final dosing regimen, and the efficacy and safety assessments are being conducted as planned.
    • 29 Jun 2023 According to an Initiator Pharma media release, this study is conducted at the MAC clinical sites in the UK.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top